Mapping and Characterizing the Development Pathway from Non-Clinical through Early Clinical Drug Development

被引：0
作者：
Stella Stergiopoulos
Kenneth A. Getz
机构：
[1] Tufts University,Tufts Center for the Study of Drug Development
来源：
Pharmaceutical Medicine | 2012年 / 26卷 / 5期
关键词：
Therapeutic Area; Median Programme; Duration Data; Informed Management Decision; Early Drug Development;
D O I：
10.1007/BF03262374
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：297 / 307
页数：10
相关论文
共 6 条
  • [1] DiMasi J.A.(2001)New drug development in the United States from 1963 to 1999 Clin Pharmacol Ther 69 286-96
  • [2] Steinmetz K.L.(2009)The basics of preclinical drug development for neurodegenerative disease indications BMS Neurol 9 S2-53
  • [3] Spack E.G.(2003)Making better drugs: decision gates in non-clinical drug development Nat Rev Drug Discov 2 542-undefined
  • [4] Pritchard J.F.(undefined)undefined undefined undefined undefined-undefined
  • [5] Jurima-Romet M.(undefined)undefined undefined undefined undefined-undefined
  • [6] Reimer M.L.(undefined)undefined undefined undefined undefined-undefined
1